- Home
- REGN vs EQNR Comparison
REGN vs EQNR Comparison
Compare REGN & EQNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REGN
- EQNR
- Stock Information
- Founded
- REGN 1988
- EQNR 1972
- Country
- REGN United States
- EQNR Norway
- Employees
- REGN N/A
- EQNR N/A
- Industry
- REGN Biotechnology: Pharmaceutical Preparations
- EQNR Integrated oil Companies
- Sector
- REGN Health Care
- EQNR Energy
- Exchange
- REGN Nasdaq
- EQNR Nasdaq
- Market Cap
- REGN 59.5B
- EQNR 64.6B
- IPO Year
- REGN 1991
- EQNR N/A
- Fundamental
- Price
- REGN $560.00
- EQNR $24.27
- Analyst Decision
- REGN Buy
- EQNR Hold
- Analyst Count
- REGN 23
- EQNR 5
- Target Price
- REGN $794.83
- EQNR $28.20
- AVG Volume (30 Days)
- REGN 972.9K
- EQNR 3.4M
- Earning Date
- REGN 10-30-2025
- EQNR 10-23-2025
- Dividend Yield
- REGN 0.63%
- EQNR 7.32%
- EPS Growth
- REGN 5.03
- EQNR N/A
- EPS
- REGN 39.67
- EQNR 3.02
- Revenue
- REGN $14,214,200,000.00
- EQNR $106,465,000,000.00
- Revenue This Year
- REGN N/A
- EQNR $0.76
- Revenue Next Year
- REGN $4.86
- EQNR N/A
- P/E Ratio
- REGN $14.12
- EQNR $7.50
- Revenue Growth
- REGN 5.38
- EQNR 1.09
- 52 Week Low
- REGN $476.49
- EQNR $21.41
- 52 Week High
- REGN $1,170.58
- EQNR $28.27
- Technical
- Relative Strength Index (RSI)
- REGN 46.27
- EQNR 46.48
- Support Level
- REGN $552.98
- EQNR $23.58
- Resistance Level
- REGN $570.76
- EQNR $24.93
- Average True Range (ATR)
- REGN 15.16
- EQNR 0.37
- MACD
- REGN -2.91
- EQNR 0.03
- Stochastic Oscillator
- REGN 16.26
- EQNR 48.93
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
About EQNR Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2023 (53% liquids) and ended 2023 with 5.2 billion barrels of proven reserves (49% liquids). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.